Human <i>RPE65</i> Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 YearArtur V. Cideciyan, Samuel G. Jacobson, William W. Hauswirth et al.|Human Gene Therapy|2009Cited by 312
Safety of Recombinant Adeno-Associated Virus Type 2–RPE65 Vector Delivered by Ocular Subretinal InjectionSamuel G. Jacobson, William W. Hauswirth, Gregory M. Acland et al.|Molecular Therapy|2006Cited by 223
Vision 1 Year after Gene Therapy for Leber's Congenital AmaurosisArtur V. Cideciyan, Samuel G. Jacobson, William W. Hauswirth et al.|New England Journal of Medicine|2009Cited by 199
Safety in Nonhuman Primates of Ocular AAV2- <i>RPE65</i> , a Candidate Treatment for Blindness in Leber Congenital AmaurosisSamuel G. Jacobson, William W. Hauswirth, Sanford L. Boye et al.|Human Gene Therapy|2006Cited by 147
Safety in Nonhuman Primates of Ocular AAV2-RPE65, a Candidate Treatment for Blindness in Leber Congenital AmaurosisSamuel G. Jacobson, William W. Hauswirth, Sanford L. Boye et al.|Human Gene Therapy|2006Cited by 12